Q-omics provides the consensus-scored WBP11P3 profile across patient tissues and cancer cell-line models. WBP11P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, WBP11P3 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, WBP11P3 RNA expression shows 6,028 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, COAD, and STAD as cancer lineages where WBP11P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WBP11P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WBP11P3 survival associations across molecular data types. WBP11P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WBP11P3 RNA expression–survival associations across cancer types. High WBP11P3 expression shows unfavorable associations in LIHC, MESO, UVM, CHOL and READ, but favorable associations in LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for WBP11P3 RNA expression.
This table summarizes WBP11P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for WBP11P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WBP11P3 shows higher tumor expression in COAD, BLCA, BRCA, STAD and READ. The COAD box plot shows higher WBP11P3 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .001).
This table shows molecular features associated with WBP11P3 in patient tissues and cancer cell lines. In patient samples, WBP11P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
